Novavax (NVAX) Covid-19 Vaccine Induces Immune Response in First Human Study, Company Says - DJ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Novavax (NVAX) PT Raised to $257 at B.Riley/FBR
August 5, 2020 6:57 AM EDTB.Riley/FBR analyst Chad L. Mabry raised the price target on Novavax (NASDAQ: NVAX) to $257.00 (from $184.00) while maintaining a Buy rating.
... MoreNovavax (NVAX) Reports Positive Phase 1 Data for COVID-19 Vaccine Candidate
August 5, 2020 6:24 AM EDTNovavax, Inc. (NASDAQ: NVAX) today announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID19 vaccine with and without MatrixM adjuvant in healthy adults 18-59 years of age. NVXCoV2373, the Companys recombinant COVID-19 vaccine candidate adjuvanted with Matrix-M, was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. The data have been submitted for peer-review to a scientific journal and to an online preprint server at medRxiv.org.
NVX-CoV2373 was well-tolerated and had a reassuring safety profile.
Overall,... More
Novavax (NVAX) Erases Post-Market Decline, Now Up 13%
August 4, 2020 5:46 PM EDTNovavax (NASDAQ: NVAX) Erases Post-Market Decline, Now Up 13%
